Comparison of quantamatrix multiplexed assay platform and genotype MTBDR assay using smear-positive sputum specimens from patients with multidrug-resistant/extensively drug-resistant tuberculosis in South Korea

Seoyong Kim, Yeun Kim, Yunhee Chang, Workneh Korma Hirgo, Chulhun L. Chang, Shim Taesun, Young Uh, Hyeyoung Lee

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Rapid detection of drug-resistant tuberculosis (DR-TB) is crucial for timely treatment and management. The GenoType MTBDRplus and MTBDRsl (MTBDR) assays have been endorsed by the World Health Organization (WHO) for the detection of DR-TB. However, MTBDR assays cannot simultaneously detect multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Furthermore, interpretation of the MTBDR assay requires trained people, and the assay has low sample throughput, processing only up to 12 samples in parallel. We have developed the Quantamatrix Multiplexed Assay Platform (QMAP) to detect MDR-/XDR-TB simultaneously. The interpretation of QMAP results is automated, and the platform can process up to 96 samples in parallel. To compare the performance of QMAP with MTBDR assays, we performed QMAP and the MTBDR assay on 76 smear-positive, Mycobacterium tuberculosis culture-positive sputum specimens. Compared with phenotypic drug susceptibility testing (DST) results, the sensitivity and specificity of QMAP were 100 and 98% for rifampin resistance, 80 and 100% for isoniazid resistance, 44.4 and 100% for ethambutol resistance, 100 and 100% for fluoroquinolone resistance, and 100 and 100% for second-line injectable drug resistance, respectively. The sensitivity and specificity of MTBDR assays were 100 and 98% for rifampin resistance, 80 and 100% for isoniazid resistance, 44.4 and 98.1% for ethambutol resistance, 100 and 100% for fluoroquinolone resistance, and 100 and 100% for second-line injectable drug resistance, respectively. The sensitivity and specificity of QMAP were 85.0 and 100%, respectively, for the detection of MDR-TB and 100 and 100%, respectively, for XDR-TB. The sensitivity and specificity of MTBDR assays was consistent with those of QMAP. Our study showed that the QMAP assay has sensitivity and specificity equivalent to that of MTBDR assays in smear-positive sputum specimens. In combination with phenotypic DST, QMAP might be useful as a supplementary DST assay for rapid detection of MDR-/XDR-TB.

Original languageEnglish
Article number1075
JournalFrontiers in Microbiology
Volume10
Issue numberMAY
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Extensively Drug-Resistant Tuberculosis
Republic of Korea
Sputum
Genotype
Sensitivity and Specificity
Ethambutol
Multidrug-Resistant Tuberculosis
Fluoroquinolones
Isoniazid
Rifampin
Drug Resistance
Pharmaceutical Preparations
Injections
Mycobacterium tuberculosis

All Science Journal Classification (ASJC) codes

  • Microbiology
  • Microbiology (medical)

Cite this

@article{01e35336631d41a88e3da4bf5aeaa054,
title = "Comparison of quantamatrix multiplexed assay platform and genotype MTBDR assay using smear-positive sputum specimens from patients with multidrug-resistant/extensively drug-resistant tuberculosis in South Korea",
abstract = "Rapid detection of drug-resistant tuberculosis (DR-TB) is crucial for timely treatment and management. The GenoType MTBDRplus and MTBDRsl (MTBDR) assays have been endorsed by the World Health Organization (WHO) for the detection of DR-TB. However, MTBDR assays cannot simultaneously detect multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Furthermore, interpretation of the MTBDR assay requires trained people, and the assay has low sample throughput, processing only up to 12 samples in parallel. We have developed the Quantamatrix Multiplexed Assay Platform (QMAP) to detect MDR-/XDR-TB simultaneously. The interpretation of QMAP results is automated, and the platform can process up to 96 samples in parallel. To compare the performance of QMAP with MTBDR assays, we performed QMAP and the MTBDR assay on 76 smear-positive, Mycobacterium tuberculosis culture-positive sputum specimens. Compared with phenotypic drug susceptibility testing (DST) results, the sensitivity and specificity of QMAP were 100 and 98{\%} for rifampin resistance, 80 and 100{\%} for isoniazid resistance, 44.4 and 100{\%} for ethambutol resistance, 100 and 100{\%} for fluoroquinolone resistance, and 100 and 100{\%} for second-line injectable drug resistance, respectively. The sensitivity and specificity of MTBDR assays were 100 and 98{\%} for rifampin resistance, 80 and 100{\%} for isoniazid resistance, 44.4 and 98.1{\%} for ethambutol resistance, 100 and 100{\%} for fluoroquinolone resistance, and 100 and 100{\%} for second-line injectable drug resistance, respectively. The sensitivity and specificity of QMAP were 85.0 and 100{\%}, respectively, for the detection of MDR-TB and 100 and 100{\%}, respectively, for XDR-TB. The sensitivity and specificity of MTBDR assays was consistent with those of QMAP. Our study showed that the QMAP assay has sensitivity and specificity equivalent to that of MTBDR assays in smear-positive sputum specimens. In combination with phenotypic DST, QMAP might be useful as a supplementary DST assay for rapid detection of MDR-/XDR-TB.",
author = "Seoyong Kim and Yeun Kim and Yunhee Chang and Hirgo, {Workneh Korma} and Chang, {Chulhun L.} and Shim Taesun and Young Uh and Hyeyoung Lee",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fmicb.2019.01075",
language = "English",
volume = "10",
journal = "Frontiers in Microbiology",
issn = "1664-302X",
publisher = "Frontiers Media S. A.",
number = "MAY",

}

Comparison of quantamatrix multiplexed assay platform and genotype MTBDR assay using smear-positive sputum specimens from patients with multidrug-resistant/extensively drug-resistant tuberculosis in South Korea. / Kim, Seoyong; Kim, Yeun; Chang, Yunhee; Hirgo, Workneh Korma; Chang, Chulhun L.; Taesun, Shim; Uh, Young; Lee, Hyeyoung.

In: Frontiers in Microbiology, Vol. 10, No. MAY, 1075, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of quantamatrix multiplexed assay platform and genotype MTBDR assay using smear-positive sputum specimens from patients with multidrug-resistant/extensively drug-resistant tuberculosis in South Korea

AU - Kim, Seoyong

AU - Kim, Yeun

AU - Chang, Yunhee

AU - Hirgo, Workneh Korma

AU - Chang, Chulhun L.

AU - Taesun, Shim

AU - Uh, Young

AU - Lee, Hyeyoung

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Rapid detection of drug-resistant tuberculosis (DR-TB) is crucial for timely treatment and management. The GenoType MTBDRplus and MTBDRsl (MTBDR) assays have been endorsed by the World Health Organization (WHO) for the detection of DR-TB. However, MTBDR assays cannot simultaneously detect multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Furthermore, interpretation of the MTBDR assay requires trained people, and the assay has low sample throughput, processing only up to 12 samples in parallel. We have developed the Quantamatrix Multiplexed Assay Platform (QMAP) to detect MDR-/XDR-TB simultaneously. The interpretation of QMAP results is automated, and the platform can process up to 96 samples in parallel. To compare the performance of QMAP with MTBDR assays, we performed QMAP and the MTBDR assay on 76 smear-positive, Mycobacterium tuberculosis culture-positive sputum specimens. Compared with phenotypic drug susceptibility testing (DST) results, the sensitivity and specificity of QMAP were 100 and 98% for rifampin resistance, 80 and 100% for isoniazid resistance, 44.4 and 100% for ethambutol resistance, 100 and 100% for fluoroquinolone resistance, and 100 and 100% for second-line injectable drug resistance, respectively. The sensitivity and specificity of MTBDR assays were 100 and 98% for rifampin resistance, 80 and 100% for isoniazid resistance, 44.4 and 98.1% for ethambutol resistance, 100 and 100% for fluoroquinolone resistance, and 100 and 100% for second-line injectable drug resistance, respectively. The sensitivity and specificity of QMAP were 85.0 and 100%, respectively, for the detection of MDR-TB and 100 and 100%, respectively, for XDR-TB. The sensitivity and specificity of MTBDR assays was consistent with those of QMAP. Our study showed that the QMAP assay has sensitivity and specificity equivalent to that of MTBDR assays in smear-positive sputum specimens. In combination with phenotypic DST, QMAP might be useful as a supplementary DST assay for rapid detection of MDR-/XDR-TB.

AB - Rapid detection of drug-resistant tuberculosis (DR-TB) is crucial for timely treatment and management. The GenoType MTBDRplus and MTBDRsl (MTBDR) assays have been endorsed by the World Health Organization (WHO) for the detection of DR-TB. However, MTBDR assays cannot simultaneously detect multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB). Furthermore, interpretation of the MTBDR assay requires trained people, and the assay has low sample throughput, processing only up to 12 samples in parallel. We have developed the Quantamatrix Multiplexed Assay Platform (QMAP) to detect MDR-/XDR-TB simultaneously. The interpretation of QMAP results is automated, and the platform can process up to 96 samples in parallel. To compare the performance of QMAP with MTBDR assays, we performed QMAP and the MTBDR assay on 76 smear-positive, Mycobacterium tuberculosis culture-positive sputum specimens. Compared with phenotypic drug susceptibility testing (DST) results, the sensitivity and specificity of QMAP were 100 and 98% for rifampin resistance, 80 and 100% for isoniazid resistance, 44.4 and 100% for ethambutol resistance, 100 and 100% for fluoroquinolone resistance, and 100 and 100% for second-line injectable drug resistance, respectively. The sensitivity and specificity of MTBDR assays were 100 and 98% for rifampin resistance, 80 and 100% for isoniazid resistance, 44.4 and 98.1% for ethambutol resistance, 100 and 100% for fluoroquinolone resistance, and 100 and 100% for second-line injectable drug resistance, respectively. The sensitivity and specificity of QMAP were 85.0 and 100%, respectively, for the detection of MDR-TB and 100 and 100%, respectively, for XDR-TB. The sensitivity and specificity of MTBDR assays was consistent with those of QMAP. Our study showed that the QMAP assay has sensitivity and specificity equivalent to that of MTBDR assays in smear-positive sputum specimens. In combination with phenotypic DST, QMAP might be useful as a supplementary DST assay for rapid detection of MDR-/XDR-TB.

UR - http://www.scopus.com/inward/record.url?scp=85068619970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068619970&partnerID=8YFLogxK

U2 - 10.3389/fmicb.2019.01075

DO - 10.3389/fmicb.2019.01075

M3 - Article

AN - SCOPUS:85068619970

VL - 10

JO - Frontiers in Microbiology

JF - Frontiers in Microbiology

SN - 1664-302X

IS - MAY

M1 - 1075

ER -